{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:11:22Z","timestamp":1788862282969,"version":"build-2803163510"},"reference-count":47,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.3724\/abbs.2026155","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:38:36Z","timestamp":1786952316000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Metformin exhibits a synergistic effect with pyrotinib by inducing ferroptosis in HER2-positive cancers through the Keap1\/Nrf2 pathway"],"prefix":"10.3724","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaixian","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","volume":"186","author":"Galogre M","year":"2023","unstructured":"Galogre M, Rodin D, Pyatnitskiy M, Mackelprang M, Koman I. A review of HER2 overexpression and somatic mutations in cancers. Crit Rev Oncol Hematol, 2023, 186:","journal-title":"Crit Rev Oncol Hematol"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/CAD.0000000000001506","volume":"34","author":"Jiang F","year":"2023","unstructured":"Jiang F, Lai J, Zhuo X, Liu L, Yang Y, Zhang J, Zhao J. HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons. Anti-Cancer Drugs, 2023, 34: 1196-1201.","journal-title":"Anti-Cancer Drugs"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/ijms25021064","volume":"25","author":"Rubin E","year":"2024","unstructured":"Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, Ergle A. Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. Int J Mol Sci, 2024, 25:","journal-title":"Int J Mol Sci"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-023-01716-y","volume":"22","author":"Xing F","year":"2023","unstructured":"Xing F, Gao H, Chen G, Sun L, Sun J, Qiao X, Xue J. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. Mol Cancer, 2023, 22:","journal-title":"Mol Cancer"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","volume":"35","author":"Ma F","year":"2017","unstructured":"Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J, Luo Y. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol, 2017, 35: 3105-3112.","journal-title":"J Clin Oncol"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"100913","DOI":"10.1016\/j.neo.2023.100913","volume":"43","author":"Chen H","year":"2023","unstructured":"Chen H, Si Y, Wen J, Hu C, Xia E, Wang Y, Wang O. P110\u03b1 inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer. Neoplasia, 2023, 43:","journal-title":"Neoplasia"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s40265-018-0997-0","volume":"78","author":"Blair HA","year":"2018","unstructured":"Blair HA. Pyrotinib: first global approval. Drugs, 2018, 78: 1751-1755.","journal-title":"Drugs"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5582\/bst.2019.01243","volume":"13","author":"Yao X","year":"2019","unstructured":"Yao X, Du N, Hu S, Wang L, Gao J. Rapid advances in research on and development of anticancer drugs in China. BST, 2019, 13: 461-463.","journal-title":"BST"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"101229","DOI":"10.1016\/j.drup.2025.101229","volume":"81","author":"Wei JR","year":"2025","unstructured":"Wei JR, Lu MY, Wei TH, Fleishman JS, Yu H, Chen XL, Kong XT. Overcoming cancer therapy resistance: from drug innovation to therapeutics. Drug Resist Updat, 2025, 81:","journal-title":"Drug Resist Updat"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"101206","DOI":"10.1016\/j.drup.2025.101206","volume":"79","author":"Zhu Q","year":"2025","unstructured":"Zhu Q, Zhang R, Zhao Z, Xie T, Sui X. Harnessing phytochemicals: innovative strategies to enhance cancer immunotherapy. Drug Resist Updat, 2025, 79:","journal-title":"Drug Resist Updat"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12943-025-02302-0","volume":"24","author":"Wang B","year":"2025","unstructured":"Wang B, Wang Z, Zhou Z, Liu G, Jiang Z, Zheng M, Geng W. Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK\/mTOR pathway. Mol Cancer, 2025, 24:","journal-title":"Mol Cancer"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1038\/s41375-022-01635-9","volume":"36","author":"Liu L","year":"2022","unstructured":"Liu L, Patnana PK, Xie X, Frank D, Nimmagadda SC, Su M, Zhang D. GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia. Leukemia, 2022, 36: 2196-2207.","journal-title":"Leukemia"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1358\/dot.2008.44.4.1138124","volume":"44","author":"Strack T null","year":"2008","unstructured":"Strack T null. Metformin: a review. Drugs Today, 2008, 44: 303-314.","journal-title":"Drugs Today"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","volume":"63","author":"Hundal RS","year":"2003","unstructured":"Hundal RS, Inzucchi SE. Metformin. Drugs, 2003, 63: 1879-1894.","journal-title":"Drugs"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/abbs\/gmaa180","volume":"53","author":"Hou Y","year":"2021","unstructured":"Hou Y, Cai S, Yu S, Lin H. Metformin induces ferroptosis by targeting miR-324-3p\/GPX4 axis in breast cancer. Acta Biochim Biophys Sin, 2021, 53: 333-341.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4161\/cc.8.1.7499","volume":"8","author":"Vazquez-Martin A","year":"2009","unstructured":"Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 2009, 8: 88-96.","journal-title":"Cell Cycle"},{"key":"CITATION17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7412","author":"Zi F","year":"2018, 15: 683\u2013690","unstructured":"Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: an existing drug for cancer prevention and therapy. Oncol Lett, 2018, 15: 683\u2013690,","journal-title":"Oncol Lett"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.21037\/tlcr-20-1072","volume":"9","author":"Huang S","year":"2020","unstructured":"Huang S, He T, Yang S, Sheng H, Tang X, Bao F, Wang Y. Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2. Transl Lung Cancer Res, 2020, 9: 2337-2355.","journal-title":"Transl Lung Cancer Res"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s43018-025-01037-7","volume":"6","author":"Ubellacker JM","year":"2025","unstructured":"Ubellacker JM, Dixon SJ. Prospects for ferroptosis therapies in cancer. Nat Cancer, 2025, 6: 1326-1336.","journal-title":"Nat Cancer"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/1061186X.2024.2399181","volume":"33","author":"Zhang S","year":"2025","unstructured":"Zhang S, Guo L, Tao R, Liu S. Ferroptosis-targeting drugs in breast cancer. J Drug Targeting, 2025, 33: 42-59.","journal-title":"J Drug Targeting"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","volume":"13","author":"Zou Y","year":"2022","unstructured":"Zou Y, Zheng S, Xie X, Ye F, Hu X, Tian Z, Yan SM. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun, 2022, 13:","journal-title":"Nat Commun"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"101942","DOI":"10.1016\/j.redox.2021.101942","volume":"41","author":"Sun J","year":"2021","unstructured":"Sun J, Zhou C, Zhao Y, Zhang X, Chen W, Zhou Q, Hu B. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biol, 2021, 41:","journal-title":"Redox Biol"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.21147\/j.issn.1000-9604.2024.02.03","volume":"36","author":"Zhang J","year":"2024","unstructured":"Zhang J, Yin G, Ye C, Feng M, Ji C, Zhou W, Wang F. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors. Chin J Cancer Res, 2024, 36: 124-137.","journal-title":"Chin J Cancer Res"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12903-024-04459-4","volume":"24","author":"Zhou L","year":"2024","unstructured":"Zhou L, Le K, Chen Q, Wang H. The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma. BMC Oral Health, 2024, 24:","journal-title":"BMC Oral Health"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41419-021-04478-x","volume":"13","author":"Wang G","year":"2022","unstructured":"Wang G, Wang Y, Yang Q, Xu C, Zheng Y, Wang L, Wu J.  Metformin prevents methylglyoxal-induced apoptosis by suppressing oxidative stress in vitro and in vivo . Cell Death Dis, 2022, 13:","journal-title":"Cell Death Dis"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.7150\/ijbs.104778","volume":"21","author":"Xie Y","year":"2025","unstructured":"Xie Y, Tian Y, Huang J, Deng W, Li X, Liu Y, Liu H. Metformin alleviates liver metabolic dysfunction in polycystic ovary syndrome by activating the Ethe1\/Keap1\/PINK1 pathway. Int J Biol Sci, 2025, 21: 3505-3526.","journal-title":"Int J Biol Sci"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"e2304521","DOI":"10.1002\/advs.202304521","volume":"10","author":"Liu X","year":"2023","unstructured":"Liu X, Yan C, Chang C, Meng F, Shen W, Wang S, Zhang Y. FOXA2 suppression by TRIM36 exerts anti-tumor role in colorectal cancer via inducing NRF2\/GPX4-Regulated ferroptosis. Adv Sci, 2023, 10:","journal-title":"Adv Sci"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"1146617","DOI":"10.3389\/fonc.2023.1146617","volume":"13","author":"Yu L","year":"2023","unstructured":"Yu L, Luo Y, Ding X, Tang M, Gao H, Zhang R, Chen M. WIPI2 enhances the vulnerability of colorectal cancer cells to erastin via bioinformatics analysis and experimental verification. Front Oncol, 2023, 13:","journal-title":"Front Oncol"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-023-01322-w","volume":"8","author":"Guan X","year":"2023","unstructured":"Guan X, Ma F, Li Q, Chen S, Fan Y, Wang J, Luo Y. Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer. Sig Transduct Target Ther, 2023, 8:","journal-title":"Sig Transduct Target Ther"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s10120-020-01126-9","volume":"24","author":"Su B","year":"2021","unstructured":"Su B, Huang T, Jin Y, Yin H, Qiu H, Yuan X. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor\/c-kit signaling and its downstream pathways. Gastric Cancer, 2021, 24: 352-367.","journal-title":"Gastric Cancer"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1186\/s12885-022-10115-3","volume":"22","author":"Olokpa E","year":"2022","unstructured":"Olokpa E, Mandape SN, Pratap S, Stewart LMV. Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells. BMC Cancer, 2022, 22:","journal-title":"BMC Cancer"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.oraloncology.2015.01.007","volume":"51","author":"R\u00eago DF","year":"2015","unstructured":"R\u00eago DF, Pavan LMC, Elias ST, De Luca Canto G, Guerra ENS. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol, 2015, 51: 416-422.","journal-title":"Oral Oncol"},{"key":"CITATION33","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1097\/CAD.0000000000001199","volume":"33","author":"Tian W","year":"2022","unstructured":"Tian W, Hao S, Wang L, Chen Y, Li Z, Luo D. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients. Anti-Cancer Drugs, 2022, 33: e622-e627.","journal-title":"Anti-Cancer Drugs"},{"key":"CITATION34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12079-021-00648-w","volume":"16","author":"Wu Z","year":"2021","unstructured":"Wu Z, Zhang C, Najafi M. Targeting of the tumor immune microenvironment by metformin. J Cell Commun Signal, 2021, 16: 333-348.","journal-title":"J Cell Commun Signal"},{"key":"CITATION35","doi-asserted-by":"publisher","first-page":"1070264","DOI":"10.3389\/fendo.2023.1070264","volume":"14","author":"Peng Q","year":"2023","unstructured":"Peng Q, Chen X, Liang X, Ouyang J, Wang Q, Ren S, Xie H. Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. Front Endocrinol, 2023, 14:","journal-title":"Front Endocrinol"},{"key":"CITATION36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12890-023-02655-6","volume":"23","author":"Deng C","year":"2023","unstructured":"Deng C, Xiong L, Chen Y, Wu K, Wu J. Metformin induces ferroptosis through the Nrf2\/HO-1 signaling in lung cancer. BMC Pulm Med, 2023, 23:","journal-title":"BMC Pulm Med"},{"key":"CITATION37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/cancers12010164","volume":"12","author":"Bebber CM","year":"2020","unstructured":"Bebber CM, M\u00fcller F, Prieto Clemente L, Weber J, von Karstedt S. Ferroptosis in cancer cell biology. Cancers, 2020, 12:","journal-title":"Cancers"},{"key":"CITATION38","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"Dixon SJ","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012, 149: 1060-1072.","journal-title":"Cell"},{"key":"CITATION39","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00432-017-2464-9","volume":"143","author":"Raza MH","year":"2017","unstructured":"Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S, Arshad M. ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol, 2017, 143: 1789-1809.","journal-title":"J Cancer Res Clin Oncol"},{"key":"CITATION40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrgentox.2018.01.007","volume":"827","author":"Najafi M","year":"2018","unstructured":"Najafi M, Cheki M, Rezapoor S, Geraily G, Motevaseli E, Carnovale C, Clementi E. Metformin: prevention of genomic instability and cancer: a review. Mutat Res Genet Toxicol Environ Mutagenesis, 2018, 827: 1-8.","journal-title":"Mutat Res Genet Toxicol Environ Mutagenesis"},{"key":"CITATION41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11010-024-05009-w","volume":"480","author":"Lai L","year":"2024","unstructured":"Lai L, Tan M, Hu M, Yue X, Tao L, Zhai Y, Li Y. Important molecular mechanisms in ferroptosis. Mol Cell Biochem, 2024, 480: 639-658.","journal-title":"Mol Cell Biochem"},{"key":"CITATION42","doi-asserted-by":"publisher","first-page":"107331","DOI":"10.1016\/j.bioorg.2024.107331","volume":"146","author":"Ma W","year":"2024","unstructured":"Ma W, Hu N, Xu W, Zhao L, Tian C, Kamei KI. Ferroptosis inducers: a new frontier in cancer therapy. Bioorg Chem, 2024, 146:","journal-title":"Bioorg Chem"},{"key":"CITATION43","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"Dodson M","year":"2019","unstructured":"Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol, 2019, 23:","journal-title":"Redox Biol"},{"key":"CITATION44","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.7150\/jca.76618","volume":"13","author":"Tang K","year":"2022","unstructured":"Tang K, Chen Q, Liu Y, Wang L, Lu W. Combination of metformin and sorafenib induces ferroptosis of hepatocellular carcinoma through p62-Keap1-Nrf2 pathway. J Cancer, 2022, 13: 3234-3243.","journal-title":"J Cancer"},{"key":"CITATION45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12943-025-02520-6","volume":"24","author":"Wu Y","year":"2025","unstructured":"Wu Y, Li H, Yue K, Jing C, Duan Y. Ferroptosis in cancer: metabolism, mechanisms and therapeutic prospects. Mol Cancer, 2025, 24:","journal-title":"Mol Cancer"},{"key":"CITATION46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"Stockwell BR","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017, 171: 273-285.","journal-title":"Cell"},{"key":"CITATION47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"Zhou B","year":"2020","unstructured":"Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol, 2020, 66: 89-100.","journal-title":"Semin Cancer Biol"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/0F49C81AC7EA48699F6156BDC64AC057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026155","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/sci-open\/api\/v1\/open\/file\/pdf\/0F49C81AC7EA48699F6156BDC64AC057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:21:56Z","timestamp":1788859316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2026155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3724\/abbs.2026155","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}